Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging.

Wang X, Kastanenka KV, Arbel-Ornath M, Commins C, Kuzuya A, Lariviere AJ, Krafft GA, Hefti F, Jerecic J, Bacskai BJ.

Sci Rep. 2018 Mar 15;8(1):4634. doi: 10.1038/s41598-018-22979-2.

2.

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics.

Goure WF, Krafft GA, Jerecic J, Hefti F.

Alzheimers Res Ther. 2014 Jul 9;6(4):42. doi: 10.1186/alzrt272. eCollection 2014. Review.

3.

Narrow-band emission in Thomson sources operating in the high-field regime.

Terzić B, Deitrick K, Hofler AS, Krafft GA.

Phys Rev Lett. 2014 Feb 21;112(7):074801. Epub 2014 Feb 21.

PMID:
24579606
4.

The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.

Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA.

Trends Pharmacol Sci. 2013 May;34(5):261-6. doi: 10.1016/j.tips.2013.03.002. Epub 2013 Apr 10.

PMID:
23582316
5.

ADDLs and the signaling web that leads to Alzheimer's disease.

Krafft GA, Klein WL.

Neuropharmacology. 2010 Sep-Oct;59(4-5):230-42. doi: 10.1016/j.neuropharm.2010.07.012. Epub 2010 Jul 23. Review.

PMID:
20650286
6.

Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers.

Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME.

Ann Neurol. 2010 Aug;68(2):220-30. doi: 10.1002/ana.22052.

7.

Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}.

Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL.

J Biol Chem. 2009 Jul 10;284(28):18742-53. doi: 10.1074/jbc.M109.011015. Epub 2009 Apr 30.

8.

Simulating oligomerization at experimental concentrations and long timescales: A Markov state model approach.

Kelley NW, Vishal V, Krafft GA, Pande VS.

J Chem Phys. 2008 Dec 7;129(21):214707. doi: 10.1063/1.3010881.

9.

Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.

Look GC, Jerecic J, Cherbavaz DB, Pray TR, Breach JC, Crosier WJ, Igoudin L, Hironaka CM, Lowe RM, McEntee M, Ruslim-Litrus L, Wu HM, Zhang S, Catalano SM, Goure WF, Summa D, Krafft GA.

Curr Alzheimer Res. 2007 Dec;4(5):562-7. Review.

PMID:
18220523
10.

Amyloid beta oligomers induce impairment of neuronal insulin receptors.

Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL.

FASEB J. 2008 Jan;22(1):246-60. Epub 2007 Aug 24.

PMID:
17720802
11.

Monoclonal antibodies that target pathological assemblies of Abeta.

Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, De Felice FG, Krafft GA, Klein WL.

J Neurochem. 2007 Jan;100(1):23-35. Epub 2006 Nov 20.

12.

The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.

Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG.

Curr Top Med Chem. 2006;6(6):597-608. Review.

PMID:
16712494
13.

Pulsed-laser nonlinear Thomson scattering for general scattering geometries.

Krafft GA, Doyuran A, Rosenzweig JB.

Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Nov;72(5 Pt 2):056502. Epub 2005 Nov 23.

PMID:
16383764
14.

Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL.

J Neurosci. 2004 Nov 10;24(45):10191-200.

15.

Spectral distributions of thomson-scattered photons from high-intensity pulsed lasers.

Krafft GA.

Phys Rev Lett. 2004 May 21;92(20):204802. Epub 2004 May 19.

PMID:
15169358
16.

Self-assembly of Abeta(1-42) into globular neurotoxins.

Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL.

Biochemistry. 2003 Nov 11;42(44):12749-60.

PMID:
14596589
17.

Energy-recovery linac project at Cornell University.

Bilderback DH, Bazarov IV, Finkelstein K, Gruner SM, Padamsee HS, Sinclair CK, Shen Q, Talman R, Tigner M, Krafft GA, Merminga L.

J Synchrotron Radiat. 2003 Sep 1;10(Pt 5):346-8. Epub 2003 Aug 28.

PMID:
12944617
18.

Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.

Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL.

Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10417-22. Epub 2003 Aug 18.

19.

In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.

Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ.

J Biol Chem. 2003 Mar 28;278(13):11612-22. Epub 2002 Dec 23.

20.

Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein.

Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, Klein WL, Krafft GA, Hong ST.

FASEB J. 2003 Jan;17(1):118-20. Epub 2002 Nov 1.

PMID:
12424218
21.

Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ.

J Biol Chem. 2002 Aug 30;277(35):32046-53. Epub 2002 Jun 10.

22.

Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL.

Brain Res. 2002 Jan 11;924(2):133-40.

PMID:
11750898
23.

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

Lambert MP, Viola KL, Chromy BA, Chang L, Morgan TE, Yu J, Venton DL, Krafft GA, Finch CE, Klein WL.

J Neurochem. 2001 Nov;79(3):595-605.

24.

Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?

Klein WL, Krafft GA, Finch CE.

Trends Neurosci. 2001 Apr;24(4):219-24. Review.

PMID:
11250006
25.
27.

Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release.

Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ.

Brain Res. 1998 Mar 2;785(2):195-206.

PMID:
9518610
28.

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53.

29.

Rapid impact of beta-amyloid on paxillin in a neural cell line.

Berg MM, Krafft GA, Klein WL.

J Neurosci Res. 1997 Dec 15;50(6):979-89.

PMID:
9452012
30.

Mechanisms of neurotoxicity associated with amyloid beta deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal.

Sayre LM, Zagorski MG, Surewicz WK, Krafft GA, Perry G.

Chem Res Toxicol. 1997 May;10(5):518-26. Review. No abstract available.

PMID:
9168248
31.
32.

Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, Bonnell BS, Emmerling MR.

J Biol Chem. 1996 Aug 23;271(34):20631-5.

33.

A beta peptide enhances focal adhesion kinase/Fyn association in a rat CNS nerve cell line.

Zhang C, Qiu HE, Krafft GA, Klein WL.

Neurosci Lett. 1996 Jun 28;211(3):187-90.

PMID:
8817572
34.
35.

The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy.

Stine WB Jr, Snyder SW, Ladror US, Wade WS, Miller MF, Perun TJ, Holzman TF, Krafft GA.

J Protein Chem. 1996 Feb;15(2):193-203.

PMID:
8924204
36.
37.

Cathepsin D from Alzheimer's-diseased and normal brains.

Kohnken RE, Ladror US, Wang GT, Holzman TF, Miller BE, Krafft GA.

Exp Neurol. 1995 Jun;133(2):105-12.

PMID:
7649217
38.

Evidence against a role for the Kunitz domain in amyloidogenic and secretory processing of the amyloid precursor protein.

Ladror US, Kohnken RE, Wang GT, Manelli AM, Frail DE, Klein WL, Holzman TF, Krafft GA.

J Neurochem. 1994 Dec;63(6):2225-30.

PMID:
7964742
39.

Focal adhesion kinase expressed by nerve cell lines shows increased tyrosine phosphorylation in response to Alzheimer's A beta peptide.

Zhang C, Lambert MP, Bunch C, Barber K, Wade WS, Krafft GA, Klein WL.

J Biol Chem. 1994 Oct 14;269(41):25247-50.

40.
41.

Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths.

Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF.

Biophys J. 1994 Sep;67(3):1216-28.

42.

Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D.

Ladror US, Snyder SW, Wang GT, Holzman TF, Krafft GA.

J Biol Chem. 1994 Jul 15;269(28):18422-8.

43.

Complement C1q does not bind monomeric beta-amyloid.

Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Krafft GA, Holzman RB, Holzman TF.

Exp Neurol. 1994 Jul;128(1):136-42.

PMID:
8070518
44.

Potential beta PP-processing proteinase activities from Alzheimer's and control brain tissues.

Ladror US, Wang GT, Klein WL, Holzman TF, Krafft GA.

J Protein Chem. 1994 May;13(4):357-66.

PMID:
7986341
45.

Synthetic approaches to continuous assays of retroviral proteases.

Krafft GA, Wang GT.

Methods Enzymol. 1994;241:70-86. Review.

PMID:
7854193
46.

Research and development challenges for Alzheimer's disease drug discovery.

Krafft GA.

Neurobiol Aging. 1994;15 Suppl 2:S57-9. No abstract available.

PMID:
7700463
47.

A continuous fluorescence assay of renin activity.

Wang GT, Chung CC, Holzman TF, Krafft GA.

Anal Biochem. 1993 May 1;210(2):351-9.

PMID:
8512070
48.

Effects of chemical modification of nitrobenzylthioinosine on its binding to high-affinity membrane binding sites and inhibition of nucleoside transport.

Ziemnicka-Merchant B, Aran JM, Plagemann PG, Krafft GA.

Biochem Pharmacol. 1992 Oct 20;44(8):1577-83.

PMID:
1417982
49.

Characterization of recombinant human renin: kinetics, pH-stability, and peptidomimetic inhibitor binding.

Holzman TF, Chung CC, Edalji R, Egan DA, Martin M, Gubbins EJ, Krafft GA, Wang GT, Thomas AM, Rosenberg SH, et al.

J Protein Chem. 1991 Oct;10(5):553-63.

PMID:
1799412
50.

Recombinant human prorenin from CHO cells: expression and purification.

Holzman TF, Chung CC, Edalji R, Egan DA, Gubbins EJ, Rueter A, Howard G, Yang LK, Pederson TM, Krafft GA, et al.

J Protein Chem. 1990 Dec;9(6):663-72.

PMID:
1963533

Supplemental Content

Loading ...
Support Center